Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Filed Chapter 11
Director departure
Appointed director
Quarterly results
|
|
K-V Pharmaceutical Co (KV.A)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/05/2013 |
8-K
| Filed for Chapter 11|
Docs:
|
"Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. and Its Affiliated Debtors",
"Order, Confirming Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. and Its Affiliated Debtors (without exhibits)",
"Share Purchase Agreement, by and among Capital Ventures International, Greywolf Capital Overseas Master Fund, Greywolf Capital Partners II LP, Greywolf Opportunities Fund LLC, Kingdon Associates, Kingdon Credit Master Fund, L.P., Kingdon Family Partnership, L.P., M. Kingdon Offshore Master Fund L.P., Deutsche Bank Securities Inc., Silver Point Finance, LLC and K-V Pharmaceutical Company",
"Second Amended and Restated Stock Purchase and Backstop Agreement, by and among Capital Ventures International, Greywolf Capital Overseas Master Fund, Greywolf Capital Partners II LP, Greywolf Opportunities Fund LLC, Kingdon Associates, Kingdon Credit Master Fund, L.P., Kingdon Family Partnership, L.P., M. Kingdon Offshore Master Fund L.P., Deutsche Bank Securities Inc., Silver Point Finance, LLC and K-V Pharmaceutical Company (without exhibits)",
"Credit and Guaranty Agreement, dated as of [ • ], by and among K-V Pharmaceutical Company, certain subsidiaries of K-V Pharmaceutical Company, as guarantors, the lenders party thereto from time to time and Law Debenture Trust Company of New York, as Administrative Agent and Collateral Agent (substantially final form) (without exhibits)" |
|
|
|